Qunsheng Ji

 VP at WuXi AppTec.

Vice President of SDDA Committee

Dr. Qunsheng Ji is VP at WuXi AppTec. He currently leads Oncology & Immunology Unit, which provides scientific solutions and services to enable cancer drug discovery and development via platforms of CRISPR gene editing, Immuno-oncology, targeted oncology and biomarker.

Prior to WuXi, Dr. Ji was Director of Translational Science, and Head of Bioscience at AstraZeneca Innovation Center China. Based in Shanghai, he was one of the pioneers who contributed to shaping and expanding the center. He also led the effort to reshape AstraZeneca’s global translational science strategy for oncology, established translational research capabilities and delivered innovative candidate drugs.

Before joined AstraZeneca, Dr. Ji gained 10 years of biotech experience in drug discovery with Onyx Pharmaceuticals and OSI Pharmaceuticals in the US, where he led a number of drug discovery projects. He received his Ph.D from Peking Union Medical College and Vanderbilt University in the US. He has published over 40 scientific papers in peer-reviewed journals.

Currently he also services as Vice Chairman of Sino Drug Discovery Association (SDDA) and member of Bayhelix.